Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Umbilical Cord MSCs for Stroke: Can They Support Recovery?
Transcript
- 0:00SPEAKER_00: Welcome to the Cyber Nicel Podcast.
- 0:02SPEAKER_00: So for decades, medicine has essentially told us that stroke recovery is well, it's this desperate race against a clock.
- 0:10SPEAKER_01: A very stressful race for patients.
- 0:11SPEAKER_00: Yeah.
- 0:12SPEAKER_00: We're told there is this brief frantic window of neuroplasticity that just permanently slams shut after a few months.
- 0:18SPEAKER_00: And that leaves patients stranded with whatever deficits remain.
- 0:22SPEAKER_00: But what if that timeline is wrong?
- 0:24SPEAKER_00: Like what if the brain is actually harboring these dormant healing processes, just waiting for the right biological signals to wake them up months or even years down the line?
- 0:34SPEAKER_01: It is a profound question.
- 0:35SPEAKER_01: And I mean, it is entirely reshaping how we view neurological rehabilitation today.
- 0:40SPEAKER_01: So we are focusing our lens on the phase of stroke recovery that happens after that initial emergency, you know, when the hospital stay is over, but traditional recovery just seems to have hit a plateau.
- 0:49SPEAKER_00: Because our mission for this deep dive is to really explore what happens when that progress stalls.
- 0:55SPEAKER_00: We are going to dig deep into the latest clinical trials and the underlying biology to understand whether exploring IV stem cell therapy for stroke recovery is a viable path forward.
- 1:06SPEAKER_00: You are about to get a clear, completely hype-free look at how researchers are attempting to support the brain during those crucial months and years following an ischemic stroke.
- 1:15SPEAKER_01: And setting a grounded, evidence-based baseline for this discussion is paramount here.
- 1:20SPEAKER_01: We will be analyzing a very specific type of cell today.
- 1:24SPEAKER_01: Umbilical cord, mesenchymal stem cells, which you'll often hear abbreviated as UCMSCs.
- 1:29SPEAKER_01: We're looking at the hard data regarding their ability to support a healing brain.
- 1:32SPEAKER_00: So no miracle cures today.
- 1:34SPEAKER_01: Let me be entirely unambiguous from the start.
- 1:36SPEAKER_01: The treatments we are discussing are being studied and applied strictly as an add-on to rigorous standard rehabilitation.
- 1:42SPEAKER_01: This is not a magic cure.
- 1:43SPEAKER_01: It absolutely does not replace the intense physical work of occupational and physical therapy.
- 1:48SPEAKER_01: Our mission today is just to look at the biology and the human trials to see what the current science actually supports.
- 1:54SPEAKER_00: Okay, let's unpack this biology first.
- 1:56SPEAKER_00: Because if you are anything like me, when you hear the phrase stem cells, your mind probably immediately jumps to bone marrow transplants.
- 2:04SPEAKER_01: Which is the legacy of the field, yeah.
- 2:05SPEAKER_00: It just sounds intensive, invasive, and incredibly difficult to match.
- 2:10SPEAKER_00: But the research we are looking at today represents a massive shift away from bone marrow.
- 2:15SPEAKER_00: So what exactly are umbilical cord MSCs and why are researchers moving in this direction?
- 2:21SPEAKER_01: Well, to understand the shift, we have to look at the source itself.
- 2:24SPEAKER_01: Historically, extracting stem cells from bone marrow involved a painful, invasive surgical procedure for the patient, or finding a donor who is a perfect genetic match.
- 2:34SPEAKER_01: Which can take months.
- 2:35SPEAKER_01: It does.
- 2:36SPEAKER_01: Umbilical cord MSCs bypass both of those hurdles entirely.
- 2:40SPEAKER_01: Specifically, clinics like Saronacell utilize a subtype known as WJMSCs.
- 2:45SPEAKER_01: These are derived from Wharton's jelly.
- 2:47SPEAKER_00: Wharton's jelly.
- 2:48SPEAKER_00: That sounds like something you'd find in a Victorian dessert.
- 2:50SPEAKER_00: What actually is that?
- 2:51SPEAKER_01: The name's a bit odd, I know.
- 2:53SPEAKER_01: But it's the gelatinous connective tissue inside the umbilical cord.
- 2:57SPEAKER_01: Its biological purpose is to insulate and protect the vital blood vessels traveling between the mother and the fetus.
- 3:04SPEAKER_00: Oh, I see.
- 3:05SPEAKER_01: And because its job is so critical to early development, that jelly is incredibly rich in young, robust mesenchymal stem cells.
- 3:14SPEAKER_00: And just to clarify the collection process for you listening, because this is always a major concern, these cords are donated after a healthy full-term birth.
- 3:22SPEAKER_00: The parents give full, informed consent to donate the tissue rather than having it discarded as medical waste.
- 3:28SPEAKER_00: So there is zero invasive procedure for the stroke patient and no ethical gray area regarding the source.
- 3:34SPEAKER_01: Furthermore, from a laboratory perspective, these specific cells are highly prized because they divide rapidly and consistently.
- 3:41SPEAKER_01: Researchers in clinical labs can cultivate them into large standardized batches, which is essential for providing reliable therapies.
- 3:49SPEAKER_00: No, it makes sense.
- 3:50SPEAKER_01: But the most significant advantage, the real reason they're replacing bone marrow in this field, comes down to the immune system.
- 3:55SPEAKER_00: This immune advantage is fascinating.
- 3:58SPEAKER_00: Let's think about a traditional bone marrow transplant, like trying to find a rare custom replacement part for a vintage classic car.
- 4:06SPEAKER_01: I like this analogy.
- 4:07SPEAKER_00: If that new part isn't an exact microscopic match to the original, the car's internal computer, which in this case is your immune system, is going to reject the part entirely and set off every alarm bell it has.
- 4:20SPEAKER_00: You need a perfect genetic match.
- 4:22SPEAKER_00: But umbilical cord MSCs act much more like universal adapter parts.
- 4:27SPEAKER_01: The biological term is immune-privileged, or at least highly immune evasive.
- 4:31SPEAKER_01: These cells have a very low expression of the specific proteins that normally trigger a recipient's immune system to attack foreign tissue.
- 4:38SPEAKER_00: So you can introduce these universal adapters into a patient's body without the immune system treating them like a hostile virus.
- 4:45SPEAKER_01: Precisely.
- 4:45SPEAKER_01: They integrate without setting off those severe immunological alarm bells, entirely bypassing the need to search national registries for a perfect genetic match.
- 4:53SPEAKER_01: And this lack of genetic matching really shapes the modern clinical landscape.
- 4:57SPEAKER_01: Well, take Cyrnes Cell, for example.
- 4:59SPEAKER_01: They're a base in Kuala Lumpur, and they treat an international patient base.
- 5:03SPEAKER_01: When families are traveling from Australia or the Middle East seeking a stroke recovery option, they are acutely aware that their recovery window is ticking.
- 5:13SPEAKER_00: Yeah, they don't have time to wait around.
- 5:15SPEAKER_01: They simply do not have the luxury of spending six months searching for a matched bone marrow donor.
- 5:20SPEAKER_01: The universal nature of UC MSEs removes that immense logistical barrier.
- 5:26SPEAKER_00: Wait, I need to put the brakes on for a second.
- 5:28SPEAKER_00: If these cells are universal adapters, what are they actually adapting to?
- 5:32SPEAKER_00: The assumption most people have is that you put stem cells into a damaged brain and they turn into new brain cells to replace the dead ones.
- 5:40SPEAKER_01: That is probably the most common misconception in regenerative medicine today.
- 5:43SPEAKER_00: So if they aren't rebuilding the brain tissue directly, how are they actually helping someone recover from a stroke?
- 5:49SPEAKER_01: For a long time, science assumes stem cells work through direct replacement, you know, literally growing into new neurons.
- 5:55SPEAKER_01: But the current consensus is that MSCs do not do this.
- 5:58SPEAKER_01: They act through complex chemical signaling.
- 6:01SPEAKER_00: So they aren't the bricklayers trying to rebuild a collapsed wall.
- 6:04SPEAKER_01: Yeah.
- 6:04SPEAKER_00: They are more like the site managers arriving at a disaster zone.
- 6:07SPEAKER_00: They aren't doing the manual labor of becoming new brain matter themselves.
- 6:12SPEAKER_00: Instead, they are walking around with blueprints, coordinating the local surviving cells and calming down the chaotic environment.
- 6:19SPEAKER_01: What's fascinating here is that the site manager analogy highlights their orchestrating role perfectly.
- 6:24SPEAKER_01: When we look at the foundational animal models, a comprehensive review of 30 different studies using mice and rats treated with umbilical cord MSCs after a stroke, the data show the infarct size, the actual area of dead brain tissue, shrank.
- 6:41SPEAKER_00: That's incredible.
- 6:42SPEAKER_01: The animals also showed improved motor function.
- 6:44SPEAKER_01: And the researchers trace this back to three specific mechanisms driven by the cell's signaling.
- 6:49SPEAKER_00: Let's break those three mechanisms down because this gets to the core of the how.
- 6:53SPEAKER_01: First is immune regulation.
- 6:55SPEAKER_01: After a stroke, the brain's immune response goes into overdrive, creating a highly toxic inflamed environment that can actually damage surviving tissue.
- 7:03SPEAKER_01: The MSEs send out chemical signals that drastically calm this inflammation.
- 7:07SPEAKER_01: Second, they reduce ongoing apoptosis in the surrounding tissue.
- 7:11SPEAKER_00: Apoptosis being programmed cell death.
- 7:14SPEAKER_01: Yes.
- 7:14SPEAKER_01: When an ischemic stroke occurs, when a clot blocks blood flow, there is a core area of brain tissue that dies quickly from oxygen starvation.
- 7:23SPEAKER_01: We cannot bring that core back.
- 7:25SPEAKER_01: But surrounding that dead core is a critical zone called the penumbra.
- 7:29SPEAKER_00: The penumbra, that's the tissue that is injured, starving, and highly inflamed, but still technically alive.
- 7:35SPEAKER_01: It is the at-risk zone.
- 7:36SPEAKER_01: The local cells in the penumbra are so stressed that they begin initiating apoptosis.
- 7:41SPEAKER_01: They start a program sequence to self-destruct.
- 7:43SPEAKER_01: Oh wow.
- 7:43SPEAKER_01: The MSEs release tiny messenger packets called exosomes, which carry those site manager blueprints you mentioned.
- 7:49SPEAKER_01: These exosomes penetrate the penumbra and deliver signals that literally tell the struggling cells to halt the self-destruct sequence.
- 7:55SPEAKER_00: Which basically saves the surrounding neighborhood from collapsing.
- 7:59SPEAKER_00: And the third mechanism Angiogenesis.
- 8:02SPEAKER_01: The formation of entirely new blood vessels.
- 8:05SPEAKER_01: The signaling encourages the brain to build new microvessels, restoring vital blood flow and oxygen to that rescued penumbra, giving it the fuel it needs to begin functioning again.
- 8:16SPEAKER_00: Animal models are the foundation, but a mouse brain is not a human brain.
- 8:20SPEAKER_00: We have to see how this translates to people.
- 8:23SPEAKER_00: And this is where the clinical trial data completely grabbed my attention.
- 8:27SPEAKER_00: Let's look at the 2025 randomized controlled trial published in Stem Cells Translational Medicine.
- 8:32SPEAKER_00: What did the study actually look at?
- 8:34SPEAKER_01: This trial was designed to compare delivery methods.
- 8:37SPEAKER_01: They enrolled 32 human patients, ranging in age from 40 to 75.
- 8:41SPEAKER_01: Every single participant was dealing with lasting neurological deficits from an ischemic stroke.
- 8:46SPEAKER_01: The researchers divided them into three groups.
- 8:49SPEAKER_01: Group one received the MSCs intravenously so, a standard 5E infusion into a vein.
- 8:56SPEAKER_01: Group two received the cells via an intrathical infusion, which means the cells were injected directly into the spinal canal to bypass the blood-brain barrier.
- 9:06SPEAKER_01: The third group was the control arm.
- 9:08SPEAKER_00: And the timeline for these patients is the part that really challenges the old dogmas.
- 9:12SPEAKER_00: They didn't just treat people the day after their stroke.
- 9:14SPEAKER_00: They treated patients anywhere from seven days to a full 24 months post-stroke.
- 9:19SPEAKER_00: We are talking about people who were two years out from their initial injury, a point where traditional medicine often says, this is as good as it gets.
- 9:27SPEAKER_01: The inclusion of patients in that chronic phase is highly significant.
- 9:31SPEAKER_01: Now, a vital structural detail of this trial: all three groups, including the two receiving the stem cells, underwent intensive standard rehabilitation.
- 9:39SPEAKER_00: So they weren't just relying on the cells alone.
- 9:41SPEAKER_01: Exactly.
- 9:42SPEAKER_01: Well, the goal was to measure whether the cells provided an additive benefit on top of standard physical therapy.
- 9:48SPEAKER_00: So measuring things like functional independence.
- 9:50SPEAKER_00: Can the patient walk better?
- 9:52SPEAKER_00: Can they hold a cup?
- 9:53SPEAKER_00: Can they communicate more clearly?
- 9:55SPEAKER_00: What did the data show when they checked in on them at the six-month mark?
- 9:58SPEAKER_00: Because here's where it gets really interesting.
- 10:01SPEAKER_01: At six months, the data diverged compellingly.
- 10:04SPEAKER_01: The intravenous group, the IV group, showed statistically significant improvements across those quality of life and stroke severity metrics compared to the rehab-only control group.
- 10:15SPEAKER_00: The IV group pulled ahead.
- 10:17SPEAKER_00: But what about the people who got the spinal injection?
- 10:19SPEAKER_01: By the 12-month mark, both the IV group and the intrafatical group demonstrated significant functional improvements over the control group, so the efficacy seemed to balance out over a longer timeline.
- 10:31SPEAKER_01: However, the determining factor that separated the two delivery methods was the safety profile.
- 10:36SPEAKER_00: The spinal route predictably came with more baggage.
- 10:38SPEAKER_01: It did.
- 10:39SPEAKER_01: The IV route demonstrated a clear safety edge, with fewer side effects overall.
- 10:43SPEAKER_01: The intrathytical route resulted in a higher incidence of procedure-related pain, specifically spinal headaches, which were a known risk when accessing the spinal fluid.
- 10:52SPEAKER_00: So the IV route is less invasive, doesn't require a spinal tap, and ultimately provided comparable functional improvements by the one year mark.
- 11:00SPEAKER_00: That sounds incredibly promising, but I am looking at that number again.
- 11:04SPEAKER_00: 32 people.
- 11:06SPEAKER_00: That is a tiny slice of the population.
- 11:08SPEAKER_01: This raises an important question.
- 11:10SPEAKER_01: It is a critical limitation that we must emphasize.
- 11:13SPEAKER_01: While it is highly encouraging that no severe, life-threatening adverse events were tied to the cells in either treatment arm, 32 individuals is statistically small.
- 11:23SPEAKER_01: A sample size of that magnitude simply cannot definitively rule out the possibility of rare risks or side effects that might only appear when treating thousands of people.
- 11:34SPEAKER_01: The authors of the study explicitly called for larger multi-center trials before these findings can be treated as absolute proof.
- 11:41SPEAKER_01: This measured caution is mandatory when evaluating early stage clinical data.
- 11:46SPEAKER_00: So if spinal delivery causes headaches and requires a specialized procedure, and IV delivery appears safer but needs more validation, did the scientific community follow up on just the IV route to see if it holds up?
- 11:58SPEAKER_01: They did.
- 11:58SPEAKER_01: The safety profile of the 2025 trial directly informed the design of a subsequent phase one trial published in 2026 in Cell Reports Medicine.
- 12:08SPEAKER_01: Because for V delivery showed such promise with fewer procedural risks, this newer trial abandoned the spinal route entirely.
- 12:14SPEAKER_00: Let's break down the setup for this one.
- 12:16SPEAKER_01: They enrolled 18 adult patients with an average age of 52.
- 12:21SPEAKER_01: All of these patients were in the subacute phase of stroke recovery, specifically three to six months post-stroke.
- 12:27SPEAKER_01: The primary objective of any phase one trial is to establish rigorous safety parameters.
- 12:32SPEAKER_01: To accomplish this, they tested three different escalating doses of the umbilical cord MSCs using only the intravenous route.
- 12:39SPEAKER_00: And how did the patients handle the escalating doses?
- 12:42SPEAKER_01: Over the six-month clinical follow-up, there were no serious side effects at any of the three dosage levels.
- 12:47SPEAKER_01: The systemic IV delivery was well tolerated across the board.
- 12:51SPEAKER_01: Furthermore, many of the participants demonstrated improved independence and lowered scores on standard stroke severity scales.
- 12:57SPEAKER_00: If I'm a patient looking at this or a family member trying to evaluate this data, I have a major question here.
- 13:02SPEAKER_00: There are 18 people, all in that three to six month window post-stroke.
- 13:08SPEAKER_00: We know that some degree of spontaneous natural recovery happens during that specific subacute phase, but there's a catch, right?
- 13:15SPEAKER_00: There was no placebo group in this one, so we can't definitively prove the cells caused the improvement.
- 13:20SPEAKER_01: You are applying the exact critical lens required for analyzing medical literature.
- 13:24SPEAKER_01: The lack of a placebo control group means this specific trial cannot be used to prove efficacy.
- 13:30SPEAKER_01: Attributing their progress solely to the stem cells would be scientifically premature.
- 13:34SPEAKER_00: So what is the actual value of a trial like this if it doesn't prove the cells work?
- 13:38SPEAKER_01: Its immense value lies in fortifying the safety profile of the delivery method.
- 13:43SPEAKER_01: By testing escalating dosages in humans without triggering severe adverse events, and by achieving this without invasive spinal access, it provides a much firmer foundation for the safety of the IV vector.
- 13:54SPEAKER_01: It confirms that introducing these universal adapter cells systemically through a standard vein is safe and well tolerated by patients who are already dealing with the complex physiological aftermath of a streak.
- 14:05SPEAKER_01: Efficacy requires phase two and phase three trials, but safety is the mandatory first hurdle and the IV route cleared it.
- 14:12SPEAKER_00: How does all of this clinical trial data translate into what a patient actually experiences today?
- 14:17SPEAKER_00: When we move from the pages of Cell Reports Medicine into a real-world clinic, how are these findings shaping treatment?
- 14:23SPEAKER_01: The accumulation of this safety and tolerance data is the exact rationale behind Saronacell's protocols.
- 14:30SPEAKER_01: They utilize 5V administration exclusively for their exosome and MSC treatments.
- 14:35SPEAKER_01: From a patient perspective, the process is remarkably straightforward.
- 14:39SPEAKER_01: It takes roughly an hour, requires only standard vein access in the arm, and completely bypasses the risks, discomfort, and recovery time associated with spinal procedures.
- 14:49SPEAKER_00: But I imagine you can't just walk in off the street, ask for an IV of stem cells, and walk out.
- 14:53SPEAKER_00: There has to be a screening process to ensure a patient's body can actually handle this biological site manager taking over.
- 14:59SPEAKER_01: The screening protocol is exhaustive, and it is a non-negotiable barrier to entry.
- 15:04SPEAKER_01: The clinical guidelines require a comprehensive review of the patient's recent brain imaging, their detailed medical history, their current medication list.
- 15:13SPEAKER_01: For instance, the clinical trials explicitly excluded patients with active infections, individuals at risk for uncontrolled bleeding, and anyone with unstable heart conditions.
- 15:22SPEAKER_00: Safety first.
- 15:23SPEAKER_01: Always.
- 15:23SPEAKER_01: So Ronacel applies these same stringent exclusion criteria.
- 15:28SPEAKER_01: It is vital to ensure that the patient's underlying physiology can safely handle the systemic signaling cascade the therapy initiates.
- 15:36SPEAKER_00: And we have to circle back to the other non-negotiable element, which you mentioned early on, rehabilitation.
- 15:41SPEAKER_00: When we looked at the 2025 trial, it wasn't just a matter of getting an IV and sitting on the couch.
- 15:47SPEAKER_00: Every single participant completed roughly 30 tailored, hour-long rehab sessions over the course of the study, focusing heavily on physical movement, speech therapy, and practicing everyday tasks.
- 15:59SPEAKER_01: The therapy and the rehabilitation are entirely interdependent.
- 16:02SPEAKER_01: One does not replace the other.
- 16:04SPEAKER_00: I like to think about it using a garden analogy.
- 16:06SPEAKER_01: Oh, how sad.
- 16:07SPEAKER_00: Well, you can think of the IV stem cell therapy as carefully preparing the soil in a garden.
- 16:12SPEAKER_00: The cells deliver the exosones, those signaling blueprints that attempt to calm the toxic inflammation and optimize the underlying cellular environment in the brain's penumbra.
- 16:22SPEAKER_00: You are making the soil incredibly nutrient-rich and ready for growth.
- 16:26SPEAKER_01: I see.
- 16:26SPEAKER_00: But standard physical and occupational therapy, that is the physical act of planting the seeds and watering them.
- 16:33SPEAKER_00: Rehab forces the brain to practice repeated motor functions and build new neural pathways.
- 16:39SPEAKER_00: You cannot expect to grow a thriving garden with perfectly prepped soil if you never actually plant any seeds.
- 16:45SPEAKER_01: That is a highly accurate way to visualize the symbiosis.
- 16:48SPEAKER_01: And if we connect this to the bigger picture of patient expectations, it requires a very firm reality check.
- 16:54SPEAKER_01: The clinical evidence points toward potential, meaningful gains in function and quality of life for carefully selected patients.
- 17:01SPEAKER_01: However, no current medical intervention, including advanced cellular therapy, is proven to restore every single patient to their exact pre-stroke baseline.
- 17:10SPEAKER_01: A complete 100% reversal of the neurological damage caused by an ischemic stroke is simply not supported by the current human data.
- 17:18SPEAKER_00: It's a tool to raise the ceiling of what is possible in recovery, but it isn't a time machine.
- 17:22SPEAKER_01: Scott on.
- 17:23SPEAKER_01: Comprehensive medical screening and an absolute commitment to sustained, rigorous rehabilitation remain the twin pillars of this approach.
- 17:32SPEAKER_01: The cells may alter the environment, but the patient must do the work to rebuild the function.
- 17:37SPEAKER_00: So, what does this all mean for you, the listener, trying to make sense of this landscape?
- 17:42SPEAKER_00: We have explored how umbilical cord-derived MSCs serve as a highly accessible, immunologically friendly cell source that doesn't require a perfect genetic match.
- 17:52SPEAKER_01: The universal adapters.
- 17:53SPEAKER_00: Yeah.
- 17:54SPEAKER_00: And we have unpacked the how, looking at how these cells operate through complex chemical signaling, like site managers handing out blueprints to calm inflammation, halt cell death, and encourage new blood vessels in the brain's penumbra.
- 18:06SPEAKER_00: And we have reviewed the clinical trial data suggesting that intravenous delivery offers a safe, well-tolerated route that, when combined with rigorous physical rehabilitation, shows measurable potential in aiding functional recovery.
- 18:19SPEAKER_01: It means that while the scientific community is still accumulating the large-scale multi-centered data required for absolute certainty, the early evidence provides a deeply compelling biological rationale.
- 18:30SPEAKER_01: The strategy of altering the brain's inflammatory microenvironment to better facilitate the hard work of physical therapy represents a significant evolution in how medicine approaches the long-term aftermath of ischemic injuries.
- 18:42SPEAKER_00: I want to leave you with a final thought to mull over.
- 18:44SPEAKER_00: For decades, our society and our medical frameworks have viewed stroke recovery as that desperate race against a clock, a frantic window of neuroplasticity that permanently slams shut, locking you into whatever deficits remain.
- 18:58SPEAKER_00: But when you look at the patients in the 2025 trial, some of whom were treated up to 24 months post-stroke long after that window supposedly closed, and who still saw functional improvements, it challenges that entire paradigm.
- 19:10SPEAKER_00: We might need to completely redefine our relationship with the brain's timeline.
- 19:14SPEAKER_00: It forces us to ask a profound question.
- 19:17SPEAKER_00: What other dormant healing processes in the human body are not actually lost to time, but are simply lying asleep, waiting for the right biological signals to wake them up?
- 19:26SPEAKER_00: If you are exploring options beyond standard rehabilitation alone and want to understand if the scientific approach aligns with your specific medical situation, it is crucial to consult with professionals who understand this data.
- 19:37SPEAKER_00: You can reach SIRENSL for a personalized review of your case by calling or messaging their WhatsApp at plus sixty eighteen two two zero zero zero three two or by emailing them directly at infocencell.com.
- 19:49SPEAKER_00: Thank you for joining us on this deep dive into the evolving, fascinating science of stroke recovery.